Sanofi CEO Hudson Delivers An Ambitious Turnaround Agenda
Executive Summary
CEO Paul Hudson came to Sanofi's capital markets day with big news and key messages for investors about the company's future business model.
You may also be interested in...
Corteria Rides Wave Of Renewed Interest In Heart Failure
A French biotech led by Philip Janiak, former head of cardiovascular research at Sanofi, is looking to bring therapies to heart failure subpopulations with high unmet needs.
Strategic M&A: Sanofi Buys Principia Biopharma For $3.7bn
Sanofi is paying for $3.68bn cash for Principia to get the US biotech’s drug development platform and nascent pipeline, including a brain-penetrant BTK inhibitor in Phase III for multiple sclerosis.
Sanofi Nabs Kymera IRAK4 Protein Degrader As It Continues To Build In I&I
Kymera will receive $150m upfront from Sanofi in a deal the big pharma views as an opportunity to develop a breakthrough oral drug for atopic dermatitis and other conditions.